An independent guide to cash-pay care. Every price is dated and sourced.

How we check

Tirzepatide in Salt Lake City: clinics and prices

Tirzepatide in Salt Lake City costs $3,887 to $5,837 a year in drug alone if bought as Zepbound from LillyDirect, depending on dose, using its October 17, 2026 prices and 28-day fills [1]. Utah Medicaid still covers Zepbound for obstructive sleep apnea with prior authorization [2].

Medical review: pending. A licensed clinician has not yet reviewed this page.

Tirzepatide is the active ingredient in Zepbound and Mounjaro, a weekly injection that acts on two gut hormone receptors, GIP and GLP-1.

Salt Lake City obesity
29.5% of adults [3]
Median household income
$75,090 [4]
Utah Medicaid, Zepbound for sleep apnea
Covered with PA [2]
Licensing lookup
Utah DOPL [5]
Zepbound per 28-day fill
$299 to $449 [1]

Zepbound, sleep apnea and Utah Medicaid

When Utah's obesity-only Medicaid pilot ended, one tirzepatide path stayed open: Utah Medicaid covers Zepbound for obstructive sleep apnea with prior authorization [2]. FDA approved that use on December 20, 2024 for adults with obesity [6]. In the label's sleep apnea trials, 42.2% and 50.2% of people on Zepbound reached remission or mild, symptom-free apnea at 52 weeks, versus 15.9% and 14.3% on placebo [7]. With 29.5% of Salt Lake City adults living with obesity [3], ask whether a sleep study makes sense.

The Sponsored box is a paid placement for a local practice. It is labeled, and we do not endorse it.

A year of cash Zepbound, by dose

LillyDirect prices and 13-fill yearly totals (prices seen Oct 17, 2026; totals are our math)
DosePer 28-day fill13 fillsRef
2.5 mg$299$3,887[1]
5 mg$399$5,187[1]
7.5 to 15 mg, refilled within 45 days$449$5,837[1]
10 to 15 mg, refill late$699$9,087[1]
Nobody stays on 2.5 mg all year; it is a starting dose only. The 7.5 mg late-refill price is $499.

Salt Lake City's median household income is $75,090 [4], so a maintenance year at $449 a fill is close to 8% of it. Refilling late at 10 mg or above pushes the year past $9,000. See tirzepatide costs and the cheapest legal ways to buy tirzepatide.

Vial or KwikPen?

  • Vial: needs a syringe that can measure 0.5 or 0.6 mL, with a new syringe and needle every injection [8].
  • KwikPen: four weekly doses in one pen, launched February 23, 2026 [9]. The label says it is not recommended for self-injection by people with impaired vision, and it must never be shared [8].
  • Medicare: the GLP-1 Bridge covers the Zepbound KwikPen but not vials or single-dose pens [10].

Staying on it versus stopping

SURMOUNT-4 tested what happens after 36 weeks of tirzepatide. People who kept taking it reached an average 25.3% weight reduction by week 88; those switched to placebo ended at 9.9%. And 89.5% of those who continued kept at least 80% of their earlier loss, compared with 16.6% on placebo [11]. That is worth weighing against the yearly cost. See stopping tirzepatide.

Compounded tirzepatide

Compounded tirzepatide is not FDA-approved [12]. FDA ended enforcement discretion for pharmacy compounding of tirzepatide in March 2025, and a federal appeals court upheld FDA's shortage decision on August 27, 2026 [13][14]. Read compounded tirzepatide.

Tirzepatide label warnings

Boxed warning for thyroid C-cell tumors in rats; do not use with a personal or family history of medullary thyroid carcinoma or MEN 2. Stop and seek care for severe stomach pain that persists or an allergic reaction. Oral birth control may work less well for 4 weeks after starting and after each dose increase, so the label advises a backup or non-oral method. Stop when pregnancy is recognized [7][15]. Call 911 in an emergency.

Check prescribers with Utah DOPL [5]. More: tirzepatide guide, tirzepatide near me, Denver, Las Vegas, Salt Lake City weight loss.

Questions people ask

How much does tirzepatide cost per year in Salt Lake City?

At LillyDirect's October 17, 2026 price of $449 per 28-day fill for 7.5 to 15 mg, 13 fills cost $5,837 for the drug alone [1].

Does Utah Medicaid cover Zepbound?

For obstructive sleep apnea, yes, with prior authorization. Obesity-only coverage was a pilot limited to renewals ending June 30, 2026 [2].

Did Zepbound help sleep apnea in trials?

In the label's 52-week trials, 42.2% and 50.2% on Zepbound reached remission or mild non-symptomatic sleep apnea, compared with 15.9% and 14.3% on placebo [7].

Does Medicare's GLP-1 Bridge cover Zepbound vials?

No. The Bridge covers the Zepbound KwikPen only, not vials or single-dose pens [10].

What happens if you stop tirzepatide?

In SURMOUNT-4, people switched to placebo after 36 weeks regained weight, ending with a 9.9% total reduction versus 25.3% for those who stayed on tirzepatide [11].

Does tirzepatide affect birth control pills?

The label says oral hormonal contraceptives may be less effective for 4 weeks after starting and after each dose increase; use a non-oral method or add a barrier method [15].

Sources

15 cited
  1. Zepbound self-pay pricing. Eli Lilly and Company (LillyDirect), accessed 2026-10-17.
  2. GLP-1 medications for weight-related comorbidities: prior authorization form. Utah Medicaid (Utah DHHS), Jun 1, 2026.
  3. PLACES place estimates: Salt Lake City, UT. CDC PLACES (2025 release, BRFSS 2023), 2025 release.
  4. QuickFacts: Salt Lake City city, Utah. U.S. Census Bureau, V2025 estimates and ACS 2020 to 2024, accessed 2026-10-17.
  5. Physician and surgeon licensing. Utah Division of Professional Licensing (DOPL), accessed 2026-10-17.
  6. FDA approves first medication for obstructive sleep apnea. U.S. Food and Drug Administration, Dec 20, 2024.
  7. Zepbound (tirzepatide) prescribing information. U.S. Food and Drug Administration, Apr 2026.
  8. Zepbound label. DailyMed, NLM, Aug 2026.
  9. Zepbound now available in multi-dose KwikPen. Eli Lilly and Company via PR Newswire, Feb 23, 2026.
  10. Medicare GLP-1 Bridge: information for pharmacies. Centers for Medicare & Medicaid Services, accessed 2026-10-17.
  11. Continued tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA (PubMed), Jan 1, 2024.
  12. FDA's concerns with unapproved GLP-1 drugs used for weight loss. U.S. Food and Drug Administration, Oct 1, 2026.
  13. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. U.S. Food and Drug Administration, Apr 1, 2026.
  14. Fifth Circuit upholds FDA GLP-1 shortage decisions. Clark Hill, Sep 10, 2026.
  15. Mounjaro label. DailyMed, NLM, Aug 2026.

This page is general information, not medical advice. Talk with a licensed clinician about your own care.

See tirzepatide prices